v3.19.2
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue:        
Grant and licensing revenue $ 342,487 $ 1,143,177 $ 1,043,549 $ 1,895,704
Operating expenses:        
Research and development 3,424,141 3,479,776 6,596,388 6,352,726
General and administrative 1,860,459 1,361,166 5,208,060 3,141,505
Change in fair value of contingent consideration 112,000 539,980 226,290 551,098
Total operating expenses 5,396,600 5,380,922 12,030,738 10,045,329
Loss from operations (5,054,113) (4,237,745) (10,987,189) (8,149,625)
Interest income 124,793 44,164 275,645 47,797
Other (expense) income, net (15,585) (53,224) (7,264) 121,796
Total non-operating income (expenses), net 109,208 (9,060) 268,381 169,593
Net loss before income taxes (4,944,905) (4,246,805) (10,718,808) (7,980,032)
Income tax expense (benefit) (235,000) 45,178 (440,000)
Net loss (4,944,905) (4,011,805) (10,763,986) (7,540,032)
Net loss - non-controlling interest (174,035) (196,734) (277,640) (403,195)
Net loss attributable to Heat Biologics, Inc. $ (4,770,870) $ (3,815,071) $ (10,486,346) $ (7,136,837)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.14) $ (0.26) $ (0.32) $ (0.72)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 33,255,724 14,727,682 33,240,529 9,894,367
Other comprehensive loss:        
Net loss $ (4,944,905) $ (4,011,805) $ (10,763,986) $ (7,540,032)
Unrealized gain on foreign currency translation 16,612 49,946 8,423 71,271
Total other comprehensive loss (4,928,293) (3,961,859) (10,755,563) (7,468,761)
Comprehensive loss attributable to non-controlling interest (174,035) (196,734) (277,640) (403,195)
Comprehensive loss $ (4,754,258) $ (3,765,125) $ (10,477,923) $ (7,065,566)

Source